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ABSTRACT
Allergic rhinitis is the most prevalent type I allergy in industrialized countries. Pollen scattering from trees or
grasses often induces seasonal allergic rhinitis, which is known as pollinosis or hay fever. The causative pollen
differs across different areas and times of the year. Impaired performance due to pollinosis andor medication
used for treating pollinosis is considered to be an important reason for the loss of concentration and productivity
in the workplace. Antigen-specific immunotherapy is an only available curative treatment against allergic rhini-
tis. Subcutaneous injection of allergens with or without adjuvant has been commonly used as an immunother-
apy; however, recently, sublingual administration has come to be considered a safer and convenient alternative
administration route of allergens. In this review, we focus on the safety and protocol of subcutaneous and sub-
lingual immunotherapy against seasonal allergic rhinitis. We also describe an approach to selecting allergens
for the vaccine so as to avoid secondary sensitization and adverse events. The biomarkers and therapeutic
mechanisms for immunotherapy are not fully understood. We discuss the therapeutic biomarkers that are cor-
related with the improvement of clinical symptoms brought about by immunotherapy as well as the involvement
of Tr1 and regulatory T cells in the therapeutic mechanisms. Finally, we focus on the current immunotherapeu-
tic approach to treating Japanese cedar pollinosis, the most prevalent pollinosis in Japan, including sublingual
immunotherapy with standardized extract, a transgenic rice-based edible vaccine, and an immunoregulatory
liposome encapsulating recombinant fusion protein.
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INTRODUCTION
Allergic rhinitis is the most prevalent type I allergy,
and pollen grains are one of the most common causes
of respiratory allergies. In western Europe, the preva-
lence of clinically confirmable allergic rhinitis was es-
timated to be 23%, with more than 50% of the allergic
subjects possessing specific IgE against grass pol-
len.1 In Japan, the prevalence of allergic rhinitis was
estimated to be 39.4% and that of pollinosis was
29.8%.2
Pollinosis is induced by the invasion of pollen
grains onto the ocular and nasal mucosa. Pollen
grains easily access internal binding sites on contact
with the aqueous phases of nasal and ocular mucosal
membranes. After pollens are hydrated on aqueous
membranes, they swell, rupture, and release their cy-
toplasmic components. It has been reported that
grass pollen grains rupture in water and release large
amounts of respirable particles, such as starch gran-
ules containing allergens.3 Although pollinosis pa-
tients have a low rate of asthma attacks during pollen
season, the attacks that do occur may be attributable
to these respirable particles bearing allergens from
pollen grains.4 Pollen grains release not only
allergen-bearing particles but also immunomodula-
tory mediators such as pollen-associated lipid media-
tors (PALMs) and NADPH oxidases. Proinflamma-
tory PALMs such as leukotriene B4-like substances
attract and activate human peripheral blood eosino-
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phils and polymorphonuclear granulocytes from both
allergic and non-allergic donors.5,6 Immunomodula-
tory PALMs, such as phytoprastanes, inhibit IL12
production in dendritic cells and Th1-type cytokine
production in antigen-specific T cells, while inducing
antigen-specific Th2 responses.7 NADPH oxidase rap-
idly increases the level of reactive oxygen species
(ROS) in lung epithelium and induces neutrophil re-
cruitment to the airway independent of the adaptive
immune responses.8,9 These reports strongly suggest
that pollen grains themselves act primarily as adju-
vants to induce pollen-antigen-specific Th2 responses
and to enhance inflammatory processes during the
elicitation phase of allergic responses.
The most common treatments against pollinosis
are medications like antihistamines, leukotriene in-
hibitors, and corticosteroids. However, these treat-
ments are not curative and sometimes induce im-
paired performance as a results of their side ef-
fects. 10,11 Antigen-specific immunotherapy can
change the natural course of allergic rhinitis and is
recognized as a curative treatment against type I al-
lergy without impaired performance. In this century,
since the first report on subcutaneous immunother-
apy (SCIT), SCIT has been developed and improved
and has become safer and more effective.12,13 Re-
cently, sublingual immunotherapy (SLIT) has been
developed and has become a safer and more benefi-
cial immunotherapy for patients.
This review focuses on the recent approach of us-
ing antigen-specific immunotherapy to treat allergic
rhinitis, and focuses especially on the use of SLIT
against pollinosis using standardized extract or re-
combinant allergens. We also discuss the therapeutic
mechanisms and therapeutic biomarkers for SLIT. Fi-
nally, we discuss the recent immunotherapeutic ap-
proach to treat Japanese cedar (Cryptomeria japon-
ica) pollinosis, which is the most common pollinosis
in Japan.
ANTIGENS FOR IMMUNOTHERAPY
For immunotherapy, extracts from an allergen
source, i.e. pollen extract, are widely used after the
concentration of their major allergen is adjusted so as
to be standardized. To standardize such extracts, it is
important to analyze their component allergens and
establish a quantification system for major aller-
gens.14 The World Allergy Organization (WAO) rec-
ommends that standardized vaccines be used for im-
munotherapy if they are available.15 However, the
protocols and methods for the standardization of al-
lergen extract are different among different suppliers,
which use their own in-house reference materials and
their own unique allergen units. This made it difficult
to compare the therapeutic effects and safety among
clinical trials involving different products. It has been
proposed that vaccines be standardized using a proto-
col based on mass units of major allergens and that
the active ingredients of the treatment be quantified.
The CREATE project has been working to select ma-
jor allergens for use in the standardization of vaccines
and to establish a quantification system and recombi-
nant allergens for the standardization.16
To improve the safety and clinical therapeutic ef-
fects of a vaccine, the selection of allergens for vacci-
nation is an important issue. Extract from pollen may
contain many allergens that cross-react with those
from fruit, vegetables, and latex. These allergens may
cause minor local side effects, especially in SLIT,
among patients who suffer from oral allergies andor
latex-fruit syndrome. Latex-fruit syndrome some-
times induces severe systematic reactions such as
anaphylactic shock in response to natural rubber and
some latex fruits.17 The cross-reactive allergens may
have to be removed from vaccines in order to avoid
severe systematic adverse reactions caused by cross-
reactivity with latex allergens for safer SLIT. For the
elucidation of reactive allergens, protein microarray
techniques have recently been applied to allergy diag-
nosis. Microarray-chip technology using a glass slide
with the immobilization of large numbers of proteins
on the surface enable us to simultaneously test IgE-
binding reactivity against large numbers of allergens
from various sources.18,19 This diagnostic technique
is applicable to the diagnosis of allergens from a sin-
gle allergen source. This component-resolved diagno-
sis is a powerful tool for selecting components of al-
lergens for immunotherapy vaccines and may im-
prove the safety and clinical therapeutic efficacy of
the vaccines in comparison to traditional immuno-
therapy using crude extract.20 Such an allergen diag-
nosis enables us to choose only IgE-binding allergens
that are individually sensitized for antigen-specific im-
munotherapy. This approach, in which only sensi-
tized allergens are used for immunotherapy, avoids
secondary additional sensitization against nonreactive
proteins that can occur with the use of crude extracts
or a mixture of allergens (Fig. 1).
Recombinant technology has been used to con-
struct vaccines for immunotherapy.21 Immunother-
apy clinical trials were performed using a mixture of
five recombinant grass allergens (rPhl p 1, rPhl p 2,
rPhl p 5a, rPhl p 5b, and rPhl p 6), and the results
suggested that a recombinant allergen vaccine can be
an effective and safe treatment to ameliorate the
symptoms of allergic rhinitis.22 Immunotherapy using
recombinant Bet v 1 was also recently reported to
show clinical efficacy, and its therapeutic effects were
comparable with those obtained using native Bet v 1
against birch pollen allergy.23
Vaccines using allergoids and modified allergens,
such as T cell-epitopes, pathogen-related molecular
pattern molecule-conjugated allergens, and others,
are under development, and some of them are consid-
ered to be promising for use as therapeutic vac-
cines.13,24
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Fig. 1 Schematic procedure of the steps involved in the identification and 
development of an individualized vaccine using only sensitized antigens for 
immunotherapy. To identify component alergens which have the capacity 
to react with serum IgE from alergic patients, it is important to establish indi-
vidualized vaccines to avoid secondary sensitization. Alergens with which 
an individual patient reacted can be elucidated by a component-based diag-
nosis, and an individualized vaccine can be established using a mixture of 
the purified native or the standardized recombinant alergens to which the 
patient is sensitized.
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Component-based
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(Plants: pollen, food, latex,
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Extract component 
proteins
Screening of IgE-binding proteins 
Production of recombinant
or fusion proteins 
Purification of each 
native allergens 
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for vaccine
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ROUTE OF VACCINE ADMINISTRATION
FOR IMMUNOTHERAPY AND ITS SAFETY
Immunotherapy vaccines against allergies were origi-
nally injected subcutaneously without an adjuvant.12
However, subcutaneous injection of allergens often
induces severe adverse reactions like local allergic re-
actions, urticaria, asthma, and frequent anaphylaxis.
To increase the safety and therapeutic efficacy of im-
munotherapy vaccines, aqueous allergen extracts ab-
sorbed into adjuvants such as aluminum hydroxide
have been used in SCIT.25 Pretreatment with antihis-
tamine or anti-IgE antibody has been used to prevent
the adverse events that can be induced after subcuta-
neous vaccine injection, and the pretreatments also
enhance the therapeutic efficacy of SCIT.26,27
In this decade, SLIT has been developed as a safer
method for immunotherapy and has been used with
increasing frequency, especially in Europe and the
US. SLIT is noted to be a very safe method without fe-
tal adverse reactions. In most cases, adverse reac-
tions to SLIT have been mild local reactions such as
oral pruritus, edema of the mouth, throat irritation,
and sneezing.28 However, a few cases of anaphylaxis
have been reported after SLIT using a crude or stan-
dardized vaccine.29-33 These reports suggest that
SLIT is not always safe for patients, especially those
with severe asthma or who have experienced severe
adverse reactions to SCIT. It has been recommended
that the first dose of the vaccine is to be administered
in a doctor’s office under observation.32
The administration regimens for SLIT, including
dosing, the build-up phase, duration of the treatment,
and frequency of the maintenance dose, differ greatly
among the clinical trials.34 The sublingual and supra-
lingual administration methods of oral drops were
evaluated by a double-blind, placebo-controlled study
using mixed standardized extract in patients allergic
to grass pollen. In this report, sublingual administra-
tion significantly reduced the nasal, ocular, and bron-
chial symptoms, as well as the intake of symptom-
reducing drugs compared to the placebo. Supralin-
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Table 1 Comparison between SLIT and SCIT
SCITSLIT
Subcutaneous injection
with or without
adjuvant
Sublingual spiting
or
sublingual swalowing
Administration
Medication or anti-IgENonePre-treatment
A few weeks or a few days for rush protocolA few weeks, one day for rush protocol, or no up-dosing phaseBuild-up phase
A few times weekly or monthlyOnce daily or a few times weeklyVaccination
Sometimes induces fetal adverse reactionsLocal mild reaction in most cases, a few reports of fetal ad-
verse reactions
Adverse event
gual treatment also attenuated the symptoms and
symptom-reducing drugs intake; however, only the
nasal symptom score showed a significant reduction
compared to the placebo-control group.35 Thus, hold-
ing the vaccine under the tongue may be an impor-
tant way to achieve better therapeutic effects with
SLIT.
Vaccines for SLIT can also be delivered by two
methods: sublingual spitting, in which the vaccine is
spat out after being held under the tongue, and sub-
lingual swallowing, in which the vaccine is swallowed
after being kept under the tongue. In studies using
radiolabeled allergens, most of the allergens re-
mained in the mouth after the vaccine was spat out.
However, plasma radioactivity began to increase only
after swallowing.36-38 The author concluded that con-
tact between the allergens and the oral mucosa is a
crucial step in the mechanisms of SLIT, and sug-
gested that the more appropriate and advantageous
way to administer the allergen sublingually is via the
sublingual swallowing procedure.38
It has been recommended that the administration
of SLIT vaccine be started at least 8 weeks before pol-
len season for better therapeutic effects.39 However,
an ultra-rush scheme of SLIT treatment for children
allergic to grass pollen was reported to significantly
improve the symptoms and the medication score
compared to the placebo group. In this 2-year ran-
domized, double-blind, placebo-control trial, the
authors administered standardized extract of five
grass pollen (Dactylis glomerata, Anthoxanthum odo-
ratum, Lolium perenne, Poa prantensis, and Phleum
pretense) beginning 2 weeks before the pollen season
started with one day for ultra-rush induction, and fol-
lowed by daily treatment (120 IR, 10 μg major aller-
gen) for 6 months. It has been reported that SLIT sig-
nificantly improved the asthma symptom score and
reduced the nasal symptom score and the use of res-
cue medication score compared to the placebo
group.40 The starting point and duration of treatment
varied among the clinical trials, and the best proce-
dure for administration remains unclear.41 (Table 1)
As a novel route to enhance the therapeutic effi-
cacy of the vaccine, direct intralymphatic injection
was proposed for the administration of peptide vac-
cine against viral infection and tumor in the mouse.
This paper reported that the direct administration of
peptide vaccine into a lymph node induced enhanced
immunogenicity compared to subcutaneous and in-
tradermal vaccination.42 This novel technique was re-
cently applied to patients with hay fever in an open-
label, randomized control trial.43 The authors injected
1,000 SQ-U of aluminum hydroxide-adsorbed grass
pollen extract into a superficial inguinal lymph node
under ultrasonic guidance. Three intralymphatic in-
jections over 2 months resulted in long-lasting toler-
ance with the amelioration of hay favor symptoms, re-
duced skin prick test reactivity, and decreased serum
allergen-specific IgE comparable with conventional
SCIT. Furthermore, the author reported that there
were fewer adverse events than in SCIT, even with-
out premedication with antihistamines, and the injec-
tion was less painful than venous puncture.43 Further
clinical trials with a larger population are needed to
evaluate the safety, therapeutic efficacy, and duration
of tolerance of this treatment.
BIOMARKERS FOR SLIT
The therapeutic effects obtained by antigen-specific
immunotherapy are commonly judged on the basis of
clinical symptoms according to quality-of-life (QOL)
score, symptom diary, and symptom-reducing drugs
intake. The biomarkers correlated with the therapeu-
tic effects are still controversial, especially for SLIT.
Antigen-specific IgG4 is considered to be a
biomarker for antigen-specific immunotherapy; how-
ever, the correlation between the induction of IgG4
production and clinical symptoms is controversial.44
In a report about the use of SLIT against timothy pol-
linosis, antigen-specific IgG4 was significantly up-
regulated in the SLIT group compared to the placebo
group, and the authors concluded that the up-
regulation of IgG4 was correlated with the improve-
ment of symptoms compared with the previous year.
However, the clinical score and medication score
were not significantly different between the SLIT
group and the placebo group.45 A recent study of
dairy administration of grass allergen tablets showed
dose-dependent efficacy of the SLIT and the induc-
tion of blocking IgG. This report showed that the ad-
ministration of 75,000 SQ-T (15 μg Phl p 5) dose sig-
nificantly reduced the symptom and medication
Immunotherapy against Allergic Rhinitis
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scores, and up-regulated specific IgG; however, a
2,500 SQ-T (0.5 μg Phl p 5) dose did not result in
amelioration of the symptom and medication scores
nor in the induction of IgG.46 We previously reported
that specific IgG4 was significantly increased in pol-
len season concomitant with improvement of the
symptom medication score in the SLIT group com-
pared to the placebo group.47 The disagreement in re-
sults related to the induction of blocking IgG or IgG4
and the improvement of clinical symptoms may de-
pend on the dose andor the method of administra-
tion of the SLIT vaccine.
Other serological parameters have been recently
reported to be useful as therapeutic biomarkers for
SLIT. A 3-month course of pre-seasonal treatment of
patients with grass pollen allergic rhinitis induced a
reduction of the serum level of soluble human leuko-
cyte antigen (sHLA)-G. The authors reported a sig-
nificant relationship among the decrease of the sHLA-
G serum level, the increase of interferon (IFN)-γ-
producing cells, and the decrease of sHLA-A, -B, and
-C after SLIT.48 Furthermore, the changes of serum
sHLA levels were significantly correlated with the
clinical symptom score measured using a visual ana-
logue scale (VAS) after SLIT.49 In this preliminary
open-labeled study, the authors suggested that sHLA
molecules might be considered as possible biomark-
ers of the response to SLIT.
Recently, two reports investigated the change of se-
rum reptin levels after SLIT. Leptin is primarily pro-
duced by adipocytes and has been reported to protect
T lymphocytes from apoptosis, regulate T cell activa-
tion, and up-regulate adhesion molecules in endothe-
lial cells.50 Furthermore, leptin was reported to modu-
late the hyporesponsiveness and proliferation of hu-
man naturally occurring Foxp3+CD25+CD4+ regula-
tory T (nTreg) cells.51 After a 3-month course of SLIT
against pollinosis, serum leptin levels were reported
to significantly correlate with symptom severity as as-
sessed by VAS of nasal symptoms in women, the
number of peripheral eosinophils in men, the aller-
gen threshold dose for allergen-specific nasal chal-
lenge in both men and women, and the medication
score in women. This 3-month course of SLIT
showed a tendency to increase serum leptin levels
compared to the levels before the SLIT, albeit the in-
crease was not significant.52 After a 2-year course of
SLIT, the serum leptin level was significantly in-
creased in men.53 The relationship between the up-
regulation of leptin by SLIT and clinical symptoms re-
mains unclear; however, the difference of the clinical
therapeutic efficacy may depend on gender and the
presence or absence of obesity.
The reduction of antigen-specific Th2 responses is
considered to be an important biomarker for antigen-
specific immunotherapy. The increase in the size of
the specific Th2 clone, which produces IL4 after be-
ing stimulated with Cry j 1 (a major allergen of the
Japanese cedar pollen), after pollen season was re-
ported to be significantly reduced in the SLIT group
compared with the placebo group in a double-blind,
placebo-controlled study of Japanese cedar pollinosis.
The increase of specific IL5-producing cells after pol-
len season was also reduced in the SLIT group, but
the reduction was not statistically significant.47 It has
also been reported that after a 2-year course of SCIT
against Japanese cedar pollinosis, B and T lympho-
cyte attenuator (BTLA) expression on CD4+ T cells
was down-regulated in untreated patients after Cry j 1
stimulation and up-regulated in SCIT-treated patients.
Furthermore, the change of BTLA expression was
negatively correlated with IL5 production. The
authors concluded that BTLA-mediated coinhibition
of IL5 production may contribute to the regulation of
allergen-specific T cell responses by antigen-specific
immunotherapy.54
The therapeutic biomarkers of SLIT in children
also remain unclear. In a study of the administration
of the SLIT treatment to children with seasonal aller-
gic rhinoconjunctivitis to grass pollen, the authors re-
ported that a 2-year course of SLIT using a standard-
ized 5-grass mixture (1.5 μgweek) did not alter the
systemic immunologic reaction of IL4, IL5, and IFN-γ
cytokine production, nor the proliferation of PBMC
after stimulation with allergens in the SLIT group
compared to the placebo group, although a positive
effect on rescue medication use was achieved by
SLIT treatment.55 However, another study reported
the up-regulation of mRNA expression in PBMC dur-
ing SLIT in children using SQ-standardized tree pol-
len extracts. The authors reported that after the
stimulation of PBMC with allergen in vitro, the
mRNA expression of signaling lymphocytic activation
molecule (SLAM) was significantly increased from
baseline after 1 year in the SLIT group receiving a
high-dose (weekly dose of 200,000 SQ-U) treatment.
This up-regulation was reported to be correlated with
IL10 and transforming growth factor-β (TGF-β)
mRNA expression. The IL18 mRNA expression was
also increased in the high-dose group over a 1-year
treatment compared to the placebo group and was re-
ported to be inversely correlated with the late-phase
skin reaction after the second study year. The
authors reported that this up-regulation of SLAM and
IL18 mRNA expression suggested the down-
regulation of Th2-type inflammatory responses by in-
creased Th1-type responses.56 Another study of SLIT
in children using SQ-standardized tree pollen extract
(weekly dose of 200,000 SQ-T, 30 μg major allergen
containing Bet v 1, Aln g 1, and Cor a 1) reported that
specific allergen-induced Foxp3 mRNA expression af-
ter a 2-year course of SLIT treatment was signifi-
cantly increased in PBMCs compared to the placebo
group and compared to the level before treatment.
Changes in allergen-induced Foxp3 expression that
significantly correlated with IL10 mRNA expression
Fujimura T et al.
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were reported in the whole study group, including
the low-dose (weekly dose of 24,000 SQ-T) group and
the placebo group, after 1- and 2-year courses of treat-
ment, and correlated with TGF-β1 mRNA after 1 year
of treatment. Furthermore, IL17A mRNA expression
was significantly correlated with symptom-medication
score (SMS) in the whole study group and especially
in the high-dose treated group. The authors con-
cluded that IL17 expression may be associated with a
poor therapeutic outcome of SLIT.57
MECHANISMS OF ANTIGEN-SPECIFIC IM-
MUNOTHERAPY
Numerous data showing that antigen-specific Th2-
type responses are down-regulated and, in contrast,
Th1-type andor regulatory T cell (Treg) responses
are up-regulated by immunotherapy have been accu-
mulated. The imbalance of the population among the
antigen-specific Th1, dominant Th2, and Treg is con-
sidered to induce sensitization and subsequent aller-
gic inflammation in response to invading allergens,
and immunotherapy may correct the imbalance of
these cells. Actually, the high frequency of IL4-
secreting Th2 cells was reported in allergic individu-
als, as was, in contrast, the dominance of IL10-
secreting Tr1 cells in healthy subjects.58 These
authors suggested that the balance between allergen-
specific Tr1 cells and Th2 cells causes the develop-
ment of the allergy.
IL10-producing regulatory cells are considered to
play a crucial role in clinical therapeutic mechanisms
in immunotherapy. In a study of SCIT using house
dust mite (HDM) extract in patients allergic to HDM,
SCIT induced the suppression of PBMC proliferation
and the suppression of IFN-γ, IL5, and IL13 produc-
tion in PBMC stimulated with Der p 1 (a major aller-
gen of HDM) at 70 days after treatment compared to
the levels before treatment. In contrast to the sup-
pression of Th1 and Th2 cytokines, the production of
both IL10 and TGF-β was significantly increased. The
report also showed that the suppression of prolifera-
tion was dependent on IL10 and TGF-β and that the
source of IL10 is CD25+CD4+ T cells.59 It has also
been reported that IL10 production was induced by
SLIT against HDM. The authors also reported the
suppression of the proliferation of PBMC stimulated
with extract of mite (Dermatophagoids farinae) and
the increase of IL10 production compared to non-
treated subjects.60 The IL10 production after 3 years
of SLIT treatment was significantly correlated
with the improvement of clinical symptoms as as-
sessed by forced expiratory flow between 25% and
75% (FEF25-75).61
In a report about the use of SLIT to treat birch pol-
linosis, the authors investigated the antigen-specific
proliferation and mRNA levels of cytokines and
Foxp3. They reported that 4 weeks of SLIT induced a
reduction in Bet v 1-specific proliferation and induced
mRNA expression of IL10 and Foxp3 in CD3+ cells
compared to the levels before SLIT. These up-
regulations of IL10 and Foxp3 mRNA expression
were not seen after 52 weeks after SLIT; however,
IFN-γ mRNA expression was significantly induced at
52 weeks after SLIT. The reduced Bet v 1-specific
proliferation was significant after both 4 and 52
weeks, and this down-regulation was dependent on
IL10 at 4 weeks. It has also been reported that nei-
ther TGF-β levels nor cell-cell contact-mediated sup-
pression of CD25+CD4+ cells were changed during
the course of SLIT.62 Another report shows the sig-
nificant reduction of IL5 mRNA expression and in-
creased IL10 expression compared to the placebo
group after 1 and 2 years of SLIT at a weekly dose of
200,000 SQ-U (30 μg major allergen) in children with
tree pollinosis. It has been reported that TGF-β ex-
pression remained low after 1 and 2 years of SLIT;
however, TGF-β expression was inversely correlated
with IL5 and positively correlated with IL10 expres-
sion after 1 year of SLIT.63
In addition to IL10-secreting Tr1 cells, Foxp3+ Treg
cells are also considered to play a crucial role in the
therapeutic effects achieved by immunotherapy (Fig.
2). It has been reported that 2 years of SCIT against
hay fever significantly induced an increase in the
number of Foxp3+CD25+ and Foxp3+CD4+ cells in the
nasal mucosa compared to the number before SCIT
and the number in untreated patients out of season.
Twenty per cent of CD3+CD25+ cells were reported to
also be Foxp3-positive, and 18% of CD3+IL10-
expressing cells were Foxp3-positive in the nasal mu-
cosa after immunotherapy. This report suggested
that the increase of Foxp3+CD25+CD3+ cells in the na-
sal mucosa was associated with the clinical efficacy
and suppression of seasonal allergic inflammation.
This report also suggested the involvement of differ-
ent types of regulatory T cells, namely IL10-secreting
Tr1 cells and adaptive or induced Foxp3-positive
Treg, in the therapeutic mechanisms of immunother-
apy.64 The involvement of Treg cells in immunother-
apy was also reported in SCIT against hymenoptera
venom allergy. In this report, the authors showed
that the numbers of peripheral Treg cells defined as
Foxp3+CD25brightCD4+ T cells were significantly in-
creased by venom immunotherapy, and the increase
of circulating Treg cells was significantly correlated
with the venom specific IgG4IgE ratio.65
Antigen-specific Tr1 and Treg cells are considered
to be involved not only in the suppression of Th2 cells
but also, directly or indirectly, in the suppression of
peripheral allergic inflammation24 (Fig. 3). It has
been reported that CD25+CD4+ Treg cells, more than
90% of which are Foxp3+, directly inhibited the FcεR1-
dependent mast cell degranulation after crosslinking
of IgE, and this inhibition was dependent on cell-cell
contact involving OX40-OX40L interactions between
Treg and mast cells in the mouse.66 Furthermore, al-
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Fig. 2 T cels in antigen-specific immunotherapy. Antigen-specific immunotherapy induces regulatory T 
cels and Th1 cels via antigen-presentation by mucosal dendritic cels (DC). Th17 cels may be induced in 
a non-responder population by immunotherapy. The induced Th1 cels and/or regulatory T cels down-
regulate the activation of Th2 cels and subsequently the activation of inflammatory cels such as eosino-
phils and mast cels. The regulatory T cels also activate B cels to produce blocking IgG or IgG4, and the 
blocking antibody inhibits binding between alergen and surface IgE on inflammatory cels to prevent the 
secretion of inflammatory chemical mediators.
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lergic human eosinophils in peripheral blood and
chronically inflamed nasal tissues were reported to
express CD40, and the cross-linking of CD40 and
CD40L enhanced the survival of eosinophils and in-
duced the release of granulocytemacrophage
colony-stimulating factor (GM-CSF). In this report,
IL10 down-regulated the constitutive expression of
CD40 mRNA expression in eosinophils.67 The induc-
tion of IL10-producing Tr1 or Treg cells in the nasal
mucosa may play an important role in the reduction
of nasal symptoms via cross-talk down-regulation of
mast cells and eosinophils.
In a reports on the rush protocol of SCIT against
Japanese cedar pollinosis using standardized pollen
extract, the percentage of CD203chigh cells in CD3−
CRTH2+ basophils after allergen stimulation was re-
ported to be down-regulated after rush immunother-
apy without a decrease of the serum specific IgE titer.
Furthermore, the percentage of CD203chigh on baso-
phils after in vitro stimulation was reported to be sig-
nificantly correlated with symptom score.68 The
mechanisms which attenuate the sensitivity of periph-
eral basophils without a change in serum specific IgE
remain unclear; however, this attenuation may be par-
tially due to the up-regulation of inhibitory blocking
antibody on the surface of basophils.
ANTIGEN-SPECIFIC IMMUNOTHERAPY
AGAINST JAPANESE CEDAR POLLINOSIS
In Japan, Japanese cedar pollinosis is one of the most
prevalent types of seasonal allergic rhinitis, with a
prevalence estimated to be 26.5%.2 Two clinical trials
described the therapeutic effects of SLIT against
Japanese cedar pollinosis.47,69 In both trials, standard-
ized Japanese cedar pollen extract was used at a
monthly cumulative dose of 8,000 JAU, which con-
tains approximately 10 μg of Cry j 1. This dosage is
less than that reported in Europe, where a dose of
75,000 SQ-T (15 μg of a major grass allergen Phl p 5)
was administered once daily for 18 weeks.46 Unless
the monthly cumulative dose is approximately 140th
of the amount required to be considered a major al-
lergen (10450 μg as a major allergen) in Japan, SLIT
with an active treatment group against Japanese ce-
dar pollinosis is still effective for improving quality of
life and significantly ameliorates patients’ SMS and
symptom score during the pollen season. The up-
regulation of the IL4-producing clone size specific to
epitopes from Cry j 1 and Cry j 270 was reported to be
significantly attenuated, and Cry j 1-specific IgG4 pro-
duction was also significantly induced by active
SLIT.47 Furthermore, IL10-producing Tr1 cells were
Fujimura T et al.
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Fig. 3 Proposed roles of regulatory T cels on inflammatory cels in 
alergen-specific immunotherapy. Regulatory T cels, namely IL10-secreting 
Tr1 cels or adaptive/induced Treg cels, down-regulate inflammatory cels, 
directly or indirectly. Regulatory T cels down-regulate the activation of Th2 
cels and subsequently Th2-type cytokine secretion. Regulatory T cels sup-
press the activation of inflammatory cels directly via their surface mole-
cules and by secreting cytokines, and indirectly via the down-regulation of 
cytokine production in Th2 cels and by the activation of B cels to produce 
blocking IgG.
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reported to be significantly increased in patients
treated with SLIT compared with the levels in un-
treated patients and healthy subjects, and the prolif-
eration of CD4+ leukocytes stimulated with Cry j 1
and Cry j 2 was significantly suppressed by SLIT
treatment in an IL10-dependent manner.71 Supple-
mentation with recombinant or native Cry j-allergens
andor updosing of the extract by bio-engineering
may lead to more effective SLIT for treating pollino-
sis.
Another approach to safer immunotherapy is the
use of oral immunotherapy using transgenic rice
seed accumulating Cry j 1.72 The generated trans-
genic rice plants expressed recombinant, structurally
disrupted Cry j 1 peptides but spanned the entire Cry
j 1 region as fusion proteins with the major rice stor-
age protein glutenin. These fusion proteins aggre-
gated with cysteine-rich prolamin and were deposited
in endoplasmic reticulum-derived protein body I in
rice seed. Transgenic rice expressing T cell epitopes
from Cry j 1 and Cry j 2 successfully suppressed
antigen-specific Th2-mediated IgE responses in a
mouse model of allergic rhinitis.73 Further clinical tri-
als are needed to develop a rice-based edible vaccine
as a tool for oral immunotherapy to control allergies.
An immunoregulatory liposome encapsulating the
recombinant fusion protein of Cry j 1-Cry j 2 was
manufactured as a novel vaccine for Japanese cedar
pollinosis without risk of anaphylaxis.74 The hybrid
fusion allergen is expected to provide safer and more
effective vaccines for immunotherapy. Vaccines using
only T cell epitopes are also safer than native aller-
gens, but there is wide variation among individual T
cell epitopes. The fusion protein of major allergens
covers all sequential T cell epitopes but is expected to
have less IgE-binding capacity because its three-
dimensional structure is disrupted in some B cell epi-
topes. Recombinant hybrid molecules using major al-
lergens of timothy grass pollen induced stronger pro-
liferation of PBMC in timothy-allergic patients than
did mixtures of corresponding allergens, but still pos-
sess IgE-binding capacity and induce IgG production
in sensitized mice.75 In a mouse model sensitized
with native Cry j 1 and Cry j 2, the vaccine that con-
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tained Cry j 1-Cry j 2 fusion protein in the im-
munoregulatory liposome showed suppression of IgE
and IgG antibody responses after being challenged
with the allergens. Furthermore, oral administration
of the vaccine showed efficient suppression of IgE an-
tibody production.74
CONCLUSIONS
The standardization of a vaccine enables us to com-
pare the results from varied clinical trials with respect
to dose, clinical effects, and changes in biological pa-
rameters. Many reports have shown positive clinical
therapeutic effects and suppressed effectorinflam-
matory responses. It is considered that IL10-
producing Tr1 andor adaptive or induced Treg cells
may be involved in the suppression of the antigen-
specific Th2-responses and local inflammation. How-
ever, how immunotherapy induces suppressor cells
like Tr1 and Treg cells remains unclear, although the
involvement of mucosal dendritic cells has been pro-
posed. High-quality clinical studies are indispensable
to clarify the therapeutic biomarkers and the mecha-
nisms of induction of suppressor cells, and the resul-
tant data from the studies may enable us to develop
safer and more effective immunotherapy through the
modification of the allergens, optimum dose, or ad-
ministration regimen of a vaccine.
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